Current
14.6×
5-Year Average
64.3×
All-Time High
1668.6×
All-Time Low
7.3×
P/FCF Ratio daily chart for Incyte (INCY)
Jun 8, 2021 – Jun 5, 2026 · 1,255 trading days
P/FCF ratio is not shown for periods when TTM free cash flow was negative.
Historical P/FCF Ratio for Incyte (INCY) from 2001 to 2025
| 2025 | $19.50B | $1.35B | 14.4× | -42.3× | |
| 2024 | $13.34B | $235.17M | 56.7× | +25.4× | |
| 2023 | $14.08B | $449.00M | 31.4× | +11.3× | |
| 2022 | $17.88B | $892.11M | 20.0× | -8.5× | |
| 2021 | $16.22B | $568.48M | 28.5× | — | |
| 2020 | $19.07B | −$311.98M | — | — | |
| 2019 | $18.84B | $632.59M | 29.8× | -21.8× | |
| 2018 | $13.55B | $262.74M | 51.6× | — | |
| 2017 | $20.00B | −$204.01M | — | — | |
| 2016 | $18.91B | $184.48M | 102.5× | -231.2× | |
| 2015 | $20.20B | $60.53M | 333.7× | — | |
| 2014 | $12.41B | −$1.62M | — | — | |
| 2013 | $8.20B | $4.91M | 1668.6× | — | |
| 2012 | $2.19B | −$97.67M | — | — | |
| 2011 | $1.90B | −$165.51M | — | — | |
| 2010 | $2.04B | $93.83M | 21.7× | -68.7× | |
| 2009 | $1.08B | $11.97M | 90.4× | — | |
| 2008 | $368.70M | −$141.56M | — | — | |
| 2007 | $848.29M | −$93.85M | — | — | |
| 2006 | $490.16M | −$51.94M | — | — | |
| 2005 | $446.66M | −$103.50M | — | — | |
| 2004 | $792.43M | −$116.06M | — | — | |
| 2003 | $495.28M | −$128.07M | — | — | |
| 2002 | $308.11M | −$70.16M | — | — | |
| 2001 | $1.29B | −$59.92M | — | — |
- 202514.4×
- 202456.7×
- 202331.4×
- 202220.0×
- 202128.5×
- 2020—
- 201929.8×
- 201851.6×
- 2017—
- 2016102.5×
- 2015333.7×
- 2014—
- 20131668.6×
- 2012—
- 2011—
- 201021.7×
- 200990.4×
- 2008—
- 2007—
- 2006—
- 2005—
- 2004—
- 2003—
- 2002—
- 2001—
About P/FCF Ratio at Incyte (INCY)
Incyte (INCY) P/FCF ratio is 14.6× as of June 5, 2026. The 5-year average is 64.3×. The sector median currently stands at 19.8×. The current ratio is at the 5th percentile of its own 10-year history.
Incyte (INCY) historical P/FCF ratio has ranged from a low of 7.3× (2010) to a high of 1668.6× (2013) in the available daily series.
The price-to-free-cash-flow (P/FCF) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) free cash flow. It is calculated as market cap ÷ TTM free cash flow, where free cash flow = operating cash flow − capital expenditures. Because FCF cannot be inflated by non-cash accounting items, P/FCF is often considered a cleaner measure of "earnings-power valuation" than P/E — especially for capital-intensive businesses where depreciation diverges from real cash outflows.
Incyte P/FCF Ratio by Year
Incyte P/FCF Ratio 2025: 14.4×
Incyte (INCY) P/FCF ratio in 2025 was 14.4×, contracted from 56.7× the prior year.
Incyte P/FCF Ratio 2024: 56.7×
Incyte (INCY) P/FCF ratio in 2024 was 56.7×, expanded from 31.4× the prior year.
Incyte P/FCF Ratio 2023: 31.4×
Incyte (INCY) P/FCF ratio in 2023 was 31.4×, expanded from 20.0× the prior year.
Incyte P/FCF Ratio 2022: 20.0×
Incyte (INCY) P/FCF ratio in 2022 was 20.0×, contracted from 28.5× the prior year.
Incyte P/FCF Ratio 2021: 28.5×
Incyte (INCY) P/FCF ratio in 2021 was 28.5×.
Sector peers by P/FCF Ratio — chart
Current ratio vs. sector peers. Highlighted bar is this company.
Sector peers by P/FCF Ratio — table
Healthcare peers of Incyte (INCY), ranked by P/FCF ratio.
| 18.5× | |
| 17.8× | |
| 17.8× | |
| 16.9× | |
| 16.9× | |
| 16.7× | |
| 16.4× | |
| 16.3× | |
| 15.9× | |
| 14.0× | |
| 13.5× | |
| 12.5× | |
| 12.4× | |
| 12.2× | |
| 12.1× | |
| 11.3× | |
| 10.7× | |
| 10.4× | |
| 10.3× | |
| 10.0× | |
| 9.6× | |
| 9.1× | |
| 9.1× | |
| 6.9× | |
| 2.5× |
- 18.5×
- 17.8×
- 16.9×
- 16.7×
- 16.4×
- 13.5×
- 12.4×
- 10.7×
- 10.3×
- 9.1×
- 9.1×
- 6.9×
- 2.5×
Frequently asked questions
Incyte (INCY) Key Financials
Charts, filings, and peer comparison for every metric